Why Trump’s ‘Made in America’ plan leaves us vulnerable

0
123

A generic drug finished in an American factory but dependent on a single overseas supplier for its active ingredient may be less secure than an imported medicine produced at two independent plants with multiple qualified suppliers.

That distinction matters as President Donald Trump moves to bring generic-drug manufacturing back to the United States. He has announced a plan to keep imported generics tariff-free until August 2028, before imposing steep tariffs intended to encourage domestic production.

The objective is reasonable. Medicines that Americans cannot afford to lose access to should be manufactured domestically wherever feasible. Yet domestic production does not necessarily mean supply security.

The FDA reported in 2025 that only 9% of manufacturers producing active pharmaceutical ingredients used in FDA-approved drugs were based in the U.S., compared with 22% in China and…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here